Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ziprasidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 13/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 11/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 8/20 | 0.98 |
| ▸ | HTR7 | P34969 | 3/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | HTR6 | P50406 | 2/20 | 0.98 |
| ▸ | MTOR | P42345 | 1/20 | 0.98 |
| ▸ | RAB9A | P51151 | 1/20 | 0.98 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.98 |
| ▸ | HTR3B | O95264 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | GOT1 | P17174 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ziprasidone SCHEMBL30354044 | 1.00 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL5565088 | 1.00 | HTR2A (0.98) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL29594402 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL2978308 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL1164202 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL930539 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL2978306 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL6061373 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL10324884 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| Ziprasidone SCHEMBL122875 | 0.99 | KCNH2 (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | claimed |
| CN-120121734-A | Method for detecting residual solvent benzene in ziprasidone hydrochloride bulk drug | 重庆锐恩医药有限公司 | 2025-06-10 | — | — | CN | claimed |
| CN-119804720-A | Liquid chromatography tandem mass spectrometry detection method of psychotropic drugs based on magnetic solid phase extraction | 天津智谱仪器有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-118975981-A | Ziprasidone hydrochloride suspension and preparation method thereof | 北京万全阳光医学技术有限公司 | 2024-11-19 | — | — | CN | claimed |
| US-11969580-B2 | Syringe systems and methods for multi-stage fluid delivery | TRUE CONCEPTS MEDICAL TECHNOLOGIES, LLC (US) | 2024-04-30 | — | — | US | claimed |
| CN-117517501-A | Ziprasidone hydrochloride, synthesis intermediate thereof and liquid chromatography detection method of impurities | 湖南省湘中制药有限公司 | 2024-02-06 | — | — | CN | claimed |
| US-20230414575-A1 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | claimed |
| CN-114344303-B | Novel psychotropic solid dispersion, preparation method and application | 江苏海洋大学 | 2023-05-09 | — | — | CN | claimed |
| CN-110325193-B | Novel medical use of compound III | 勃林格殷格翰国际有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-112778298-B | Impurities in ziprasidone hydrochloride and preparation method thereof | 海南鑫开源医药科技有限公司 | 2023-02-24 | — | — | CN | claimed |
| EP-1181018-A1 | ZIPRASIDONE SUSPENSION | Pfizer Products Inc. (US) | 2002-02-27 | — | — | EP | claimed |
| EP-1175900-A2 | Use of growth hormone secretagogues for improvement of fucnctional health status | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| WO-2000072847-A1 | ZIPRASIDONE SUSPENSION | PFIZER PRODUCTS INC. (US) | 2000-12-07 | — | — | WO | claimed |
| US-6150366-A | CRYSTALLINE ZIPRASIDONE FREE BASE OR CRYSTALLINE ZIPRASIDONE HYDROCHLORIDE PARTICLES WITH SPECIFIC PARTICLE SIZE ARE USEFUL AS ANTIPSYCHOSIS AGENT | PFIZER INC. (US) | 2000-11-21 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| EP-0965343-A2 | Ziprasidone formulations | Pfizer Products Inc. (US) | 1999-12-22 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| US-5206366-A | Process for preparing aryl piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1993-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | HTR2A 965/4885DRD2 3656/4885HTR2C 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.